Bristol-Myers Squibb (BMY) free cash flow

Free cash flow · fiscal 2025
$12.85B

Bristol-Myers Squibb (BMY) generated free cash flow of $12.85B in fiscal 2025 (the year ended December 31, 2025). That is 7.9% lower than the $13.94B of fiscal 2024. Figures as of 18 Nov 2026, 12:18 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
$12.85B
Change on fiscal 2024
−7.9%
Growth, 5 years
−0.7% a year
Growth, 10 years
+25.9% a year
Highest on record
$15.23Bfiscal 2021
Lowest on record
$1.29Bfiscal 2015
Fiscal years on record
192007–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Bristol-Myers Squibb free cash flow, in more detail

Over the five fiscal years to 2025 free cash flow shrank at a compound 0.7% a year; over ten years the rate was 25.9% a year. Across the 19 fiscal years on record (2007–2025), the highest was $15.23B in fiscal 2021 and the lowest $1.29B in fiscal 2015.

History · 19 fiscal years

Free cash flow by fiscal year

Bristol-Myers Squibb free cash flow, year by year

Bristol-Myers Squibb (BMY) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025$12.85B 7.9% down
2024$13.94B 10.2% up
2023$12.65B 5.9% up
2022$11.95B 21.6% down
2021$15.23B 14.5% up
2020$13.30B 80.3% up
2019$7.37B 20.6% up
2018$6.12B 44.9% up
2017$4.22B 129.0% up
2016$1.84B 43.4% up
2015$1.29B 51.0% down
2014$2.62B 12.8% down
2013$3.01B 52.9% down
2012$6.39B 42.9% up
2011$4.47B 10.0% up
2010$4.07B 21.9% up
2009$3.34B 20.6% up
2008$2.77B 19.7% up
2007$2.31B—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Bristol-Myers Squibb and comparable companies
CompanyFree cash flowFiscal year
Vertex Pharmaceuticals VRTX$3.19B2025
Medtronic MDT$5.43B2026
Bristol-Myers Squibb BMY$12.85B2025
Stryker SYK$4.28B2025
McKesson MCK$5.41B2026
Sanofi SNY€7.21B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BMY

Bristol-Myers Squibb, figure by figure

Bristol-Myers Squibb (BMY) overview: price, valuation and scorecardAll health care companies by market value

Bristol-Myers Squibb free cash flow: questions and answers

What is Bristol-Myers Squibb's free cash flow?

Bristol-Myers Squibb (BMY) generated free cash flow of $12.85B in fiscal 2025 (the year ended December 31, 2025). That is 7.9% lower than the $13.94B of fiscal 2024.

What is the growth rate of Bristol-Myers Squibb's free cash flow?

Over the five fiscal years to 2025 free cash flow shrank at a compound 0.7% a year; over ten years the rate was 25.9% a year.

What are the highest and lowest free cash flow figures on record for Bristol-Myers Squibb?

Across the 19 fiscal years on record (2007–2025), the highest was $15.23B in fiscal 2021 and the lowest $1.29B in fiscal 2015.

How is Bristol-Myers Squibb's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Bristol-Myers Squibb it is on record here for 19 fiscal years, 2007 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Bristol-Myers Squibb (BMY) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/BMY/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.